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Diabetes has been associated with higher COVID-19 related mortality, but the relationship between modifiable 
risk factors, including hyperglycaemia and obesity, with COVID-19 related mortality among people with 
diabetes is unclear. 
Methods 
National population data on people with Type 1 and Type 2 diabetes in England were linked to mortality records 
from 2nd January 2017 to 11th May 2020. The associations between risk factors and COVID-19 related mortality 
were investigated by Cox proportional hazards models.    
Findings 
Between 16th February and 11th May 2020, weekly death registrations in people with Type 1 and Type 2 
diabetes exceeded the corresponding 2017-19 three-year weekly averages by 50·9% and 64·3% respectively. 
Among 264,390 people with Type 1 and 2,874,020 people with Type 2 diabetes, there were 464 and 10,525 
COVID-19 related deaths respectively, of which 62·3% and 55·4% occurred in people with prior cardiovascular 
or renal disease.  Older age, renal impairment, non-white ethnicity and previous stroke and heart failure were 
associated with higher COVID-19 related mortality.  The hazard ratio (HR) for people with an HbA1c 
≥86mmol/mol compared to 49-53mmol/mol was 2·23 (95% CI 1·50-3·30) in Type 1 diabetes and 1·61 (1·47-
1·77) in Type 2 diabetes. The relationship between body mass index (BMI) and COVID-19 related mortality 
was U-shaped. Compared to a BMI of 25-29·9kg/m2, the HRs for a BMI <20kg/m2 and BMI ≥ 40 kg/m2 were 
2·45 (1·60 – 3·75) and  2·33 (1·53-3·56) respectively for Type 1 and  2·33 (2·11-2·56) and 1·60 (1·47-1·75) 
respectively for Type 2 diabetes.  
Interpretation  
Deaths in people with Type 1 and Type 2 diabetes rose sharply during the initial COVID-19 pandemic in 
England. Higher COVID-19 related mortality was associated not only with cardio-renal complications of 
diabetes but, independently, with glycaemic control.  
Funding 
NHS England & Improvement, NHS Digital   
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Research in context  
Evidence before this study  
From March 2020, we performed weekly searches of PubMed and MedRxiv using the terms COVID-19, SARS-
CoV-2, coronavirus, SARS virus and diabetes. Although previous studies have identified diabetes as a risk 
factor for mortality with COVID-19 in selected populations, it is unclear whether that increased risk is found in 
all types of diabetes and whether the association with diabetes is confounded by other known risk factors such 
as age, male sex, social deprivation, black, Asian and minority ethnic (BAME) ethnicity, obesity, renal disease, 
hypertension and cardiovascular disease. The detailed relationship between the level of prior glycaemic control 
and COVID-19 related mortality in people with diabetes in a population-based study, stratified by the two main 
types of diabetes with comprehensive inclusion of potential confounders, has not previously been investigated 
systematically.   
Added value of this study  
This population cohort study of people with diagnosed diabetes in England demonstrated that the COVID-19 
pandemic was associated with a sharp rise in mortality in people with both Type 1 and Type 2 diabetes 
compared to the same time of year in the previous three years. Many, but not all, additional deaths had COVID-
19 recorded on the death certificate. The study further demonstrated that COVID-19 related mortality in people 
with both Type 1 and Type 2 diabetes was associated not only with the risk factors found in all people i.e. age, 
male sex, social deprivation, non-white ethnicity, established cardiovascular disease and impaired renal 
function, but also with the level of preceding hyperglycaemia (HbA1c) and with both obesity and underweight.  
Raised preceding blood pressure was associated with lower COVID-19 related mortality but in people with 
Type 2 diabetes treatment for hypertension was associated with very slightly higher risk while statin therapy 
was associated with a lower risk. By using a contemporary comparison of mortality and risk factors in people 
with diabetes who did and who did not have recognised COVID-19 related death, similarities and differences in 
associations with risk factors were observed. 
Implications of all the available evidence  
Improved achievement of standard diabetes care recommendations that target prevention of cardio-renal, lower 
limb and ocular complications may also serve to modify some of the risk factors that we have found to be 
associated with COVID-19 mortality.  It would seem important therefore to further strengthen clinical services 
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By 11th May 2020, 4,252,290 people worldwide, from 213 countries and territories, were known to have had 
Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2 infection, and 287,131 had died.1 One third of 
COVID-19 deaths in hospital have been in people with diabetes.2 This excess burden in people with diabetes is 
similar to previous coronavirus epidemics; the prevalence of diabetes was approximately 50% in Middle East 
respiratory syndrome (MERS), and in severe acute respiratory syndrome (SARS), diabetes was an independent 
predictor of mortality and morbidity.3-6  
Diabetes, cardiovascular disease and hypertension are the most common chronic co-morbidities in people with 
severe COVID-19.7-16  We present two papers as linked publications.  In the other paper, we demonstrate that 
the odds of dying in hospital with COVID-19 were 3·51 (95% CI 3·16-3·90) for Type 1 diabetes and 2·03 
(1·97-2·09) for Type 2 diabetes compared to those without diagnosed diabetes.2 An association between in-
hospital hyperglycaemia and poorer outcomes with COVID-19 has been suggested, 12, 13 and hyperglycaemia is 
associated with increased severity of other infections.18, 19  Although one study found preceding glucose control 
to be a risk factor,20 others did not.15, 17 It is possible that hyperglycaemia may modulate the hyperimmune 
response found in life-threatening COVID-19.21 
For this paper, we analysed COVID-19 related mortality by diabetes type from a cohort consisting of 98% of all 
people with diagnosed diabetes in England using a national dataset linked to national civil death registrations 
(hospital and community). We report weekly mortality before and during the pandemic and investigate the 
associations between risk factors and COVID-19 related mortality. 
Methods 
Data sources 
The National Diabetes Audit (NDA) has collated data on people with diagnosed diabetes registered with a 
healthcare provider in England since 2003 (see Supplementary information for full details). 22  These data were 
linked using unique NHS number to Hospital Episode Statistics (HES), a record of all hospital admissions in 
England, and to civil death registrations collated by the Office for National Statistics (ONS).   
The legal basis for the NDA data collection and linkage is a Direction from NHS England to NHS Digital 
according to section 254 of the Health and Social Care Act (HSCA) for England 2012.23 Data are not extracted 
if the person has registered their dissent from permission to use their record for secondary analysis which is 
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estimated to apply to less than 1% of records.24 NHS England and NHS Digital are the joint data controllers. 
Data linkage and analysis are undertaken within NHS Digital. In March 2020, the Secretary of State for Health 
and Social Care used powers under the UK Health Service (Control of Patient Information) Regulations 2002 to 
require organisations to process confidential patient information for the purposes of protecting public health, 
providing healthcare services to the public and monitoring and managing the COVID-19 outbreak and incidents 
of exposure. 
Study population, observation period and outcomes  
Individuals included in any NDA data collection were used to quantify the number of deaths from all causes in 
all settings, registered each week during the first 19 weeks of 2017, 2018, 2019 and 2020. 
The study population comprised individuals with Type 1 or Type 2 diabetes from the latest full extract of the 
NDA, covering the period 1st January 2018 to 31st March 2019, whose most recent General Practice was in 
England and who were alive on 16th February 2020.  People with a recorded date of birth giving an age of 110 
or greater were excluded from the analysis. Individuals were linked to HES (data available from 1st April 2017 
to 31st December 2019) and to ONS recorded deaths between 16th February and 11th May 2020. COVID-19 
related death was defined as a death where an International Classification of Diseases (ICD) version 10 code 
U07.1 (COVID-19, virus identified) or U07.2 (COVID-19, virus not identified) was recorded as either a primary 
underlying or secondary cause of death.    
Definitions of exposures 
Age was grouped as <40 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years and ≥80 years. Social 
deprivation was defined by the Indices of Multiple Deprivation 2019 based on individual home postcode.26  
Ethnicity was classified as Asian, black, mixed, white, other ethnic groups, or missing.  Individuals were 
allocated to one of seven regions based on their home postcode to adjust for the geographical variation in 
SARS-CoV-2 exposure in England.   
We included data on the latest HbA1c, systolic blood pressure, total serum cholesterol and estimated glomerular 
filtration rate (eGFR) recorded between 1st January 2019 and 31st December 2019. HbA1c data was categorised 
as <48 mmol/mol, 48-53 mmol/mol, 54-58 mmol/mol, 59-74 mmol/mol, 75-85 mmol/mol, and ≥86 mmol/mol 
or missing.  Systolic blood pressure was categorised as ≤ 140mmHg, >140mmHg or missing and serum total 
cholesterol as <5mmol/l, ≥5mmol/l or missing.  People who had received one or more prescriptions for anti-
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hypertensive drugs or statins between 1st January and 31st December 2019 were identified from General Practice 
prescribing records.  The Modification of Diet in Renal Disease (MDRD) formula was used to calculate eGFR 
and results were grouped as <15ml/min/1.73m2, 15-29ml/min/1.73m2, 30-44ml/min/1.73m2, 45-59 
ml/min/1.73m2, 60-89ml/min/1.73m2 and ≥90ml/min/1.73m2 or missing.  Body mass index (BMI) and smoking 
status were identified using the latest recorded measurement between 1st January 2017 and 31st December 2019. 
BMI was grouped as <20 kg/m2, 20-24·9 kg/m2, 25-29·9 kg/m2, 30-34·9 kg/m2, 35-39·9 kg/m2, ≥40 kg/m2 or 
missing.  Smoking status was identified as current smoker, ex-smoker, non-smoker (not a current smoker but 
not known if they previously smoked), never smoker or missing.   
A history of myocardial infarction (ICD-10 codes I21-22), stroke (ICD-10 codes I61, I63-64 and I67.9) and 
heart failure (ICD-10 code I50) were identified from HES between 1st April 2017 and 31st December 2019 as 
either the primary or one of up to 14 secondary diagnoses.    
Statistical analysis 
The weekly number of deaths in people with Type 1 and Type 2 diabetes during the first 19 weeks of 2020 were 
identified.  The percentage change from the mean number of deaths for the corresponding weeks in 2017, 2018 
and 2019 was calculated.   
We created Cox proportional hazards survival analysis models with COVID-19 related death as the outcome for 
Type 1 and Type 2 diabetes respectively.  Deaths without COVID-19 recorded on the death certificate were 
treated as a censoring event.  A corresponding model was created with death without COVID-19 recorded as the 
outcome and deaths from COVID-19 treated as a censoring event.  Hazard ratios (HRs) associated with 
demographic characteristics (age, sex, social deprivation, ethnicity, region of residence), clinical characteristics 
(HbA1c, duration of diagnosed diabetes, BMI, systolic blood pressure, prescription for anti-hypertensive drugs, 
total serum cholesterol, prescription for statins, smoking status),  and co-morbidities (history of myocardial 
infarction, stroke, heart failure and eGFR) were identified for people with Type 1 and Type 2 diabetes.  Kaplan-
Meier curves and plots of Schoenfeld residuals were created to assess the proportionality of hazard over time for 
each variable included in the models.  The large cohort size meant that plots were restricted to random samples 
of 10,000.  Separate models were run for males, females, those aged less than 70 years and those aged 70 and 
older.  Given the greater numbers of people with Type 2 diabetes compared to Type 1 diabetes, individual 
models were run for each ethnicity, social deprivation quintile and BMI category in those with Type 2 diabetes.   
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Sensitivity analyses were undertaken restricting the definition of COVID-19 related death to those where it was 
identified only as the primary cause of death, and separately to deaths where only the code U07.1 was used. 
Statistical significance was defined as p-value <0.05 and confidence intervals (CI) were set at 95%.  Statistical 
calculations were undertaken in SAS Enterprise Guide 7.1 (https://support.sas.com/en/software/enterprise-
guide-support.html).  All numbers taken directly from the National Diabetes Audit are rounded to the nearest 
five persons to protect confidentiality.   
Results 
Between 16th February 2020 and 11th May 2020 there were 1604 and 36,291 deaths from all causes in people 
with Type 1 and Type 2 diabetes respectively.  A total of 10,989 deaths (464 Type 1 and 10,525 Type 2 
diabetes) had COVID-19 included on the death certificate of which 10,417 (94·7%) had COVID-19 as the 
underlying cause of death.  Comparison of the weekly number of deaths registered in people with Type 1 and 
Type 2 diabetes in 2020 with the previous three years showed an increase in mortality from mid-March 2020 
(Figure 1).  In this same period, the number of death registrations exceeded the mean number of deaths for the 
corresponding weeks in 2017, 2018 and 2019 by 672 (50·9%) and 16,071 (64·3%) in people with Type 1 and 
Type 2 diabetes respectively.  Of the additional deaths, 70·0% and 68·3% had COVID-19 recorded on the death 
certificate.   
There were 264,390 people with Type 1 diabetes and 2,874,020 people with Type 2 diabetes included in the 
NDA and alive on the 16th February 2020, and therefore included in the survival analysis.  The characteristics of 
these people are provided in Table 1; the mean ages were 46·6 years (standard deviation 19.6) for Type 1 and 
67·5 years (standard deviation 13.4) for Type 2 diabetes. Of the people with Type 1 diabetes 5·6% were of 
Asian ethnicity and 3·5% of black ethnicity.  For Type 2 diabetes, the corresponding figures were 14·0% and 
4·8% respectively.  Among people with Type 1 diabetes, 11·4% had a last reported HbA1c of 75-85 mmol/mol 
and 11·8% ≥86 mmol/mol.  A quarter (25·1%) of people with Type 2 diabetes had a last reported HbA1c of 
<48mmol/mol and 6·1% ≥86 mmol/mol.  A history of cardiovascular or renal disease (defined as myocardial 
infarction, stroke, heart failure or eGFR < 60 ml/min/1.73m2) was found in 12·0% of those with Type 1 diabetes 
and 21·7% of people with Type 2 diabetes (Table 1).   
Results from the survival analysis showed that older age and male sex were associated with higher COVID-19 
related mortality for both Type 1 and Type 2 diabetes (Figure 2).  In Type 1 diabetes, COVID-19 related 
mortality was higher in black and Asian ethnicities compared to those of white ethnicity, with HRs of 1·77 (95% 
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CI 1·25-2·49) and 1·57 (1·16-2·12) respectively. There was no significant difference for those of mixed 
ethnicity. In Type 2 diabetes, risks were higher in people of black, Asian and mixed ethnicities with HRs of 1·63 
(1·51-1·77), 1·08 (1·01-1·15) and 1·30 (1·10-1·55) respectively (Figure 2).  The higher HRs for COVID-19 
related mortality in people from all non-white ethnicities (apart from mixed ethnicity in Type 1 diabetes) 
contrasts with lower HRs for non-COVID-19 related mortality during the same period (see Supplementary 
information, Table S2). All non-white ethnicity HRs for COVID-19 related death were higher in people aged 
<70 years (Supplementary information, Table S5).   
There was a clear relationship between COVID-19 related death and social deprivation among people with 
diabetes of either type. The HR for COVID-19 related mortality for people with Type 1 diabetes in the most 
deprived quintile was 1·93 (1·36–2·72) compared to people living in the least deprived quintile. For Type 2 
diabetes, the HR was 1·46 (1·37-1·56), significantly higher than observed for non-COVID-19 related mortality 
(1·26, 1·21-1·32). The HR gradient between social deprivation and COVID-19 related mortality was steeper in 
those of Asian ethnicity (Supplementary information, Table S6) with a HR of 2·17 (1·68-2·81) for the most 
deprived quintile compared to the least deprived.  
Preceding hyperglycaemia was strongly associated with COVID-19 related death after adjusting for other risk 
factors.  Compared to those whose latest HbA1c was 49-53mmol/mol, HRs were 1·22 (1·15–1·30) and 1·61 
(1·47-1·77) for those with Type 2 diabetes whose most recent  HbA1c was 59-74 mmol/mol and ≥86mmol/mol 
respectively.  Though a similar pattern was seen in people with Type 1 diabetes, statistical significance was only 
achieved in those whose most recent HbA1c ≥ 86 mmol/mol (2·23 (1·50-3·30)). The HR for low HbA1c 
(<48mmol/mol) was 1·11 (1·05–1·18) in people with Type 2 diabetes and was similar, but not significant, in 
people with Type 1 diabetes (1·37 (0·89–2·09)).  For those with Type 2 diabetes, the gradient of the HRs 
between HbA1c level and COVID-19 related mortality was steeper in those aged < 70 years (see Supplementary 
information, Table S5).   
There was a U-shaped relationship between COVID-19 related mortality and BMI. For those with Type 1 
diabetes compared to a BMI 25-29.9 kg/m2, the HRs for BMIs <20 kg/m2, 35-39·9kg/m2 and ≥40 kg/m2were 
2·45 (1·6 –3·75),  1·72 (1·21-2·46) and 2·33 (1·53-3·56) respectively. For Type 2 diabetes, the corresponding 
HRs were 2·33 (2·11-2·56), 1·17 (1·08-1·26) and 1·60 (1·47-1·75) respectively.  This pattern of risk differed 
from that observed for non-COVID-19 related deaths during the same period, where a BMI 35-39·9 kg/m2 was 
not associated with higher mortality (see Supplementary information, Table S2). The HRs associated with 
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obesity were significantly greater in people aged < 70 compared to those ≥ 70 years (see Supplementary 
information, Table S5).   
Impaired renal function was associated with higher HRs for COVID-19 related death. Individuals with Type 1 
diabetes and impaired renal function (eGFR of 30-44 mL/min/1.73m2) had a HR of 2·46 (1·72-3·52) compared 
to those with eGFR ≥90 mL/min/1.73m2, while the HR for an eGFR of less than 15 mL/min/1.73m2 was 8·35 
(5·50–12·7).  The corresponding HRs for people with Type 2 diabetes were 1·76 (1·63-1·89) and 4·91 (4·34-
5·56) respectively.  Impaired renal function was associated with even greater hazard ratios in younger people 
(aged < 70 years) and those of Asian ethnicity (see Supplementary information, Tables S5, S6).    
Previous hospital stays for stroke or heart failure were associated with increased COVID-19 related mortality in 
both Type 1 and Type 2 diabetes, and for myocardial infarction in Type 2 diabetes (see Figure 2).  In people 
with Type 2 diabetes a history of one or more prescriptions for anti-hypertensive drugs was associated with 
higher COVID-19 related mortality whilst a prescription for statins was associated with lower mortality. A 
history of cardiovascular or renal disease was present in 62·3% and 55·4% of COVID-19 related deaths in Type 
1 and Type 2 diabetes respectively.   
After adjustment for other risk factors, being a current smoker with Type 2 diabetes was associated with lower 
COVID-19 related mortality (0·67, 0·62–0·74).  This finding was consistent across all ethnicities, social 
deprivation, and BMI categories and more marked in those aged < 70 (See Supplementary information, Table 
S5, S6, S7 and S8).  This contrasted with the HR for current smokers of 1·40 (1·34-1·47) for non-COVID-19 
related deaths in the same time period (Supplementary information, Table S2).   
In a sensitivity analysis, if deaths were limited to only those with COVID-19 recorded as a primary cause or to 
only those using the ICD-10 code  U07.1 (indicating a positive test for the SARS-CoV-2 virus) the results of the 
survival models were not materially different (Supplementary information, Table S3).   
Discussion 
We have demonstrated in an analysis of more than 98% of people with diagnosed Type 1 and Type 2 diabetes in 
England, that there was a rapid and sizeable increase in deaths from all causes in people with Type 1 and Type 2 
diabetes after the emergence of COVID-19. The data suggest that, at the peak, approximately 3,500 additional 
deaths per week occurred in people with diabetes, the majority of which had COVID-19 recorded on the death 
certificate.     
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There was an independent association between HbA1c and COVID-19 related mortality in both types of 
diabetes. In people with Type 2 diabetes, risk was significantly higher in those with an HbA1c >58mmol/mol 
than in those with an HbA1c 49-53 mmol/mol and increased with higher HbA1c levels. In one study of an 
undifferentiated population of people with diabetes,20 deaths from COVID-19 were higher if preceding HbA1c 
was >58mmol/mol but no relationship was found in three other studies, possibly due to small sample sizes.13, 15, 
17 Our observations show that the risk of COVID-19 related mortality is significantly and independently related 
to the preceding level of hyperglycaemia in people with Type 1 and Type 2 diabetes and in Type 2 diabetes this 
risk relationship is steeper in those aged < 70 years. Hyperglycaemia is known to impair host defences including 
granulocyte and macrophage function.  People with diabetes are at increased risk of many serious infections.18 
Poor glycaemic control has been associated with serious infections and hospitalisation19 and is hypothesised to 
amplify the hyperimmune response associated with severe COVID-19.21 
With respect to the other cardiometabolic targets of routine diabetes care, higher systolic blood pressure was 
weakly associated with lower COVID-19 related death, whereas treatment of hypertension was associated with 
higher mortality and prescription of statins with lower mortality. Whilst these data are of interest, it is 
impossible to draw conclusions about the potential direct impacts of anti-hypertensive drugs or statins on 
COVID-19 related mortality. However, as these medications prevent cardiovascular and renal disease, their 
continued use will help lessen not only non-COVID-19 related mortality but may contribute to reducing future 
COVID-19 related mortality.      
The independent association of BMI with risk of COVID-19 related death in these diabetes populations was U-
shaped, with a nadir at a BMI 25-29·9 kg/m2. The higher risk seen in people with lower BMI may reflect 
confounding by factors that are associated with weight loss either not included in our analysis (unmeasured 
confounding) or for which we have only imperfectly adjusted (residual confounding).  The elevated risk of 
COVID-19 related death in people with diabetes and obesity is significant and differs from that observed in non-
COVID-19 related deaths in the same period. The excess risk associated with higher BMI is also more marked 
in younger people and those of Asian and black ethnicity. This evidence adds to other reports indicating that 
obesity is an important risk factor for death from COVID-19.21  However, the association detected between BMI 
≥40 kg/m2 and COVID-19 related mortality in people with Type 2 diabetes (HR 1·60 (95% CI 1·47-1·75)) was 
less than in a study of the general English population (HR 1·92 (95% CI 1·72-2·13)20 and weaker than we 
observed in people with Type 1 diabetes (HR 2·33 (95% CI 1·53-3·56)). If the mechanisms behind this 
association involve, as speculated,21 metabolic abnormalities linked to excess ectopic fat, the pathway to 
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developing Type 2 diabetes, then an attenuated association of obesity with mortality risk may be expected in 
those who already have Type 2 diabetes. Several of the independent associations with COVID-19 related death 
are risk factors which are not readily clinically modifiable (age, sex, ethnicity and social deprivation) and mirror 
findings in other recent analyses.7-12,16-17,20 
Our comparison with deaths in the same period in which COVID-19 was not recorded highlights the importance 
of these risk factors. While the effect of age is similar, male sex and socio-economic deprivation have a steeper 
relationship with COVID-19 related mortality than with other causes of mortality. The higher COVID-19 related 
mortality risk seen in people with diabetes from black or Asian ethnic groups is a reversal of the pattern seen in 
non-COVID-19 related deaths during the period examined and in observations of mortality pre-pandemic.27  By 
contrast the associations of previous myocardial infarction, stroke and heart failure with COVID-19 related 
mortality were similar to those for other deaths but established renal disease appeared to have stronger 
association with COVID-19 related mortality.  
Current smoking, compared to having never smoked, was associated with a lower risk of COVID-19 related 
mortality.  This is the reverse of what was observed in non-COVID-19 related mortality and has been described 
elsewhere.20  It was seen across all BMI categories and all ethnicities.  Being an ex-smoker was associated with 
a higher risk of both COVID-19 related and non-COVID-19 related mortality.  This unexpected finding may be 
the result of confounding by yet unidentified factors or collider bias, and it should not be inferred at this stage 
that smoking is protective, although another condition characterised by abnormal inflammation, ulcerative 
colitis, has shown protective effects of smoking.28 More research is needed into this finding. 
Comparison with other studies 
One retrospective study from 88 US hospitals of 451 people with COVID-19 and diabetes or hyperglycaemia 
reported that uncontrolled hyperglycaemia was associated with longer length of stay and higher mortality.12 
However, the definition of diabetes was unclear, and this was contemporary rather than preceding 
hyperglycaemia.  Another retrospective study from China of 952 people with Type 2 diabetes (total cohort 
7337) reported that well controlled inpatient blood glucose (glycaemic variability within 3·9 to 10·0 mmol/L) 
was associated with a lower in-hospital mortality compared to individuals with poorly controlled glycaemia 
(adjusted HR, 0·14).13  Recent publications from France17 and China,15 of modest non-population-based cohorts 
of people with Type 2 diabetes did not find any relationship between HbA1c and COVID-19 outcome.  The 
OpenSAFELY Collaborative20 also took a population approach linking English primary care data from 
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approximately 17 million individuals to COVID-19 related mortality data. Diabetes (type not specified) was 
independently associated with a higher risk of death, with an adjusted HR of 1·31 for those with HbA1c 
<58mmol/mol, and of 1·95 for those with HbA1c ≥58mmol/mol. Our work has established a strong case that the 
level of preceding hyperglycaemia in people with both Type 1 and Type 2 diabetes is an independent risk factor 
for whole population COVID-19 related mortality (in the community and in hospital).  
Strengths and limitations  
A strength of our study is that it includes nearly all people with diagnosed Type 1 and Type 2 diabetes in 
England and data regarding risk factors from prior to the COVID-19 pandemic. The results are therefore likely 
to be applicable to other countries with similar populations and healthcare systems.  The analysis of mortality 
among people with diabetes who died without a diagnosis of COVID-19 provides a valuable comparison group. 
However, potential limitations of comparing deaths with an infectious, mainly pulmonary disease (albeit leading 
to systemic harm), with deaths predominantly due to cardiovascular disease and cancers, should be 
acknowledged. It is noted that the number of deaths labelled as non-COVID-19 related (deaths without COVID-
19 included on the death certificate) also rose during the study period.  The ONS in England considers it likely 
that many of these additional deaths, highlighted in Figure 1, were due to undiagnosed COVID-19;29 any under-
recognition of COVID-19 related mortality will have attenuated the observed associations provided under-
recognition was non-differential.   
In our supplementary data, after stratifying the population by age the associations of HbA1c, BMI and renal 
impairment were somewhat stronger in younger people in whom co-morbidity and frailty are less prevalent.  
The variables included in this analysis were limited to those collated by the National Diabetes Audit which do 
not include many non cardiometabolic related comorbidities such as respiratory disease, liver disease, alcohol 
use or cognitive impairment, potentially leading to confounding due to lack of measurement.  Residual 
confounding may also occur with a single measurement to identify baseline characteristics.   
The lack of population level data on tests for COVID-19 means it is not possible to identify whether the 
associations between risk factors and COVID-19 related mortality are due to increased susceptibility to 
infection, more severe illness following infection or a combination of both.  Our endpoint of all deaths where 
COVID-19 was identified as a cause of death provides a measure of disease severity independent of clinical 
decisions, administrative arrangements and resource availability, which are all possible influences on hospital 




While several risk factors identified for COVID-19 related mortality in people with diabetes cannot readily be 
modified, HbA1c can be influenced by healthcare interventions. Although the association with obesity was more 
complex, particularly in the Type 2 diabetes population, weight can also be influenced by healthcare 
interventions and is a goal of routine care.  Improved achievement of standard diabetes care recommendations 
that target prevention of cardio-renal, lower limb and ocular complications would also serve to modify some of 
the risk factors that we have found to be associated with COVID-19 related mortality.  The nature of the 
COVID-19 pandemic means it would be implausible to seek randomised controlled trial evidence that 
improving achievement of diabetes care treatment targets would result in better outcomes in people with 
diabetes. However, there is every reason to advocate continued adherence to guidance. It would seem important 
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Tables and Figures 
Table 1: Baseline characteristics on 16th February 2020 and number (%) of subsequent COVID-19 related 
deaths in people with Type 1 (n= 264,390) and Type 2 diabetes (n=2,874,020) in England  
    Type 1 diabetes Type 2 diabetes 






   
  
  Male 149,680  56·6% 284 61·2%   1,606,430  55·9% 6456 61·3% 






   
  
  <40 years 100,860  38·1% 6 1·3%        67,845  2·4% 24 0·2% 
  40-49 years   41,745  15·8% 17 3·7%      213,180  7·4% 98 0·9% 
  50-59 years    9,220  18·6% 56 12·1%      520,480  18·1% 485 4·6% 
  60-69 years   36,230  13·7% 84 18·1%      724,990  25·2% 1274 12·1% 
  70-79 years   24,290  9·2% 115 24·8%      769,175  26·8% 2694 25·6% 
  ≥ 80 years   12,045  4·6% 186 40·1%      578,345  20·1% 5950 56·5% 
Deprivation   
  
  
   
  
  Most deprived   56,280  21·3% 133 28·7%      700,915  24·4% 2817 26·8% 
  2nd most deprived   54,260  20·5% 106 22·8%      641,610  22·3% 2558 24·3% 
  3rd least deprived   53,345  20·2% 109 23·5%      575,030  20·0% 1983 18·8% 
  2nd least deprived   51,360  19·4% 67 14·4%      513,925  17·9% 1692 16·1% 
  Least deprived   48,975  18·5% 49 10·6%      440,990  15·3% 1468 13·9% 
  Missing        175  0·1% 0 0·0%          1,555  0·1% 7 0·1% 
Region   
  
  
   
  
  London   33,330  12·6% 106 22·8%      466,165  16·2% 2557 24·3% 
  South West   27,525  10·4% 28 6·0%      271,770  9·5% 590 5·6% 
  South East   41,540  15·7% 42 9·1%      401,810  14·0% 1331 12·6% 
  Midlands   53,210  20·1% 120 25·9%      584,905  20·4% 2061 19·6% 
  East of England   32,590  12·3% 61 13·1%      312,035  10·9% 980 9·3% 
  North West   32,170  12·2% 52 11·2%      373,310  13·0% 1493 14·2% 
  North East   43,850  16·6% 55 11·9%      462,480  16·1% 1506 14·3% 
  Missing        175  0·1% 0 0·0%          1,555  0·1% 7 0·1% 
Ethnicity   
  
  
   
  
  Asian   14,725  5·6% 60 12·9%      403,355  14·0% 1313 12·5% 
  Black     9,310  3·5% 47 10·1%      137,695  4·8% 884 8·4% 
  Mixed     3,230  1·2% * -        30,885  1·1% 133 1·3% 
  Other     4,035  1·5% 11 2·4%        47,570  1·7% 164 1·6% 
  White 210,415  79·6% 314 67·7%   1,897,575  66·0% 7105 67·5% 
  Missing   22,675  8·6% 28 6·0%      356,945  12·4% 926 8·8% 
HbA1c   
  
  
   
  
  <48 mmol/mol   17,950  6·8% 50 10·8%      721,950  25·1% 2789 26·5% 
  49-53 mmol/mol   21,550  8·2% 38 8·2%      591,815  20·6% 1811 17·2% 
  54-58 mmol/mol   25,200  9·5% 31 6·7%      365,955  12·7% 1151 10·9% 
  59-74 mmol/mol   77,380  29·3% 133 28·7%      551,530  19·2% 1988 18·9% 
  75-85 mmol/mol   30,150  11·4% 55 11·9%      157,030  5·5% 588 5·6% 
  ≥86 mmol/mol   31,280  11·8% 76 16·4%      174,835  6·1% 674 6·4% 
  Missing HbA1c   60,885  23·0% 81 17·5%      310,905  10·8% 1524 14·5% 
Duration   
  
  
   
  
  < 1 year        840  0·3% * -        25,940  0·9% 53 0·5% 
  2-3 years   14,690  5·6% 6 1·3%      378,905  13·2% 728 6·9% 
  4-5 years    16,335  6·2% * -      374,960  13·0% 877 8·3% 
  5-9 years   37,465  14·2% 18 3·9%      792,110  27·6% 2158 20·5% 
  10-14 years   39,940  15·1% 45 9·7%      628,730  21·9% 2315 22·0% 
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  15-20 years   42,820  16·2% 108 23·3%      426,890  14·9% 2378 22·6% 
  ≥20 years 112,305  42·5% 282 60·8%      246,475  8·6% 2016 19·2% 
Body mass index   
  
  
   
  
  <20 kg/m2   19,990  7·6% 28 6·0%        42,160  1·5% 488 4·6% 
  20-24·9 kg/m2   73,950  28·0% 109 23·5%      398,390  13·9% 2143 20·4% 
  25-29·9 kg/m2    82,005  31·0% 107 23·1%      905,290  31·5% 2962 28·1% 
  30-34·9 kg/m2   42,095  15·9% 98 21·1%      743,100  25·9% 2097 19·9% 
  35-39·9 kg/m2   15,455  5·8% 44 9·5%      367,230  12·8% 975 9·3% 
  ≥40 kg/m2     8,160  3·1% 29 6·3%      241,570  8·4% 676 6·4% 
  Missing   22,740  8·6% 49 10·6%      176,280  6·1% 1184 11·2% 
Systolic blood pressure (mmHg) 
   
  
   
  
  ≤ 140 mmHg 173,870  65·8% 301 64·9%   1,922,985  66·9% 7141 67·8% 
  >140 mmHg   44,750  16·9% 124 26·7%      690,215  24·0% 2602 24·7% 
  Missing   45,775  17·3% 39 8·4%      260,825  9·1% 782 7·4% 
On anti-hypertensive drugs   
  
  
   
  
  Yes 115,660  43·7% 393 84·7%   2,185,920  76·1% 9241 87·8% 
  No 146,040  55·2% 65 14·0%      665,825  23·2% 1200 11·4% 
  Missing     2,685  1·0% 6 1·3%        22,215  0·8% 84 0·8% 
Total cholesterol   
  
  
   
  
  ≤5mmol/l 133,765  50·6% 282 60·8%   1,935,740  67·4% 6694 63·6% 
  >5mmol/l    46,635  17·6% 65 14·0%      508,185  17·7% 1416 13·5% 
  Missing   83,990  31·8% 117 25·2%      430,100  15·0% 2415 22·9% 
On statins   
  
  
   
  
  Yes 118,995  45·0% 338 72·8%   2,099,505  73·1% 7355 69·9% 
  No 142,710  54·0% 120 25·9%      752,245  26·2% 3086 29·3% 
  Missing     2,685  1·0% 6 1·3%        22,215  0·8% 84 0·8% 
Smoking status   
  
  
   
  
  Current smoker   43,365  16·4% 41 8·8%      368,515  12·8% 568 5·4% 
  Ex-smoker   61,605  23·3% 175 37·7%   1,006,465  35·0% 4509 42·8% 
  Non-smoker     6,245  2·4% 12 2·6%        50,480  1·8% 280 2·7% 
  Never smoked 139,525  52·8% 236 50·9%   1,446,110  50·3% 5150 48·9% 
  Missing smoking status   13,645  5·2% 0 0·0%          2,460  0·1% 18 0·2% 
eGFR 
   
  
   
  
  ≥90 ml/min/1.73m22 125,475  47·5% 76 16·4%   1,072,390  37·3% 1989 18·9% 
  60-89 ml/min/1.73m2   72,940  27·6% 127 27·4%   1,225,575  42·6% 3721 35·4% 
  45-59 ml/min/1.73m2    13,445  5·1% 89 19·2%      307,705  10·7% 2060 19·6% 
  30-44 ml/min/1.73m2     7,475  2·8% 72 15·5%      145,560  5·1% 1577 15·0% 
  15-29 ml/min/1.73m2     3,280  1·2% 42 9·1%        40,195  1·4% 644 6·1% 
  <15 ml/min/1.73m2     1,845  0·7% 38 8·2%        10,560  0·4% 315 3·0% 
  Missing   39,925  15·1% 20 4·3%        72,040  2·5% 219 2·1% 
Co-morbidities   
  
  
   
  
  Previous MI     3,095  1·2% 31 6·7%        48,340  1·7% 425 4·0% 
  Previous stroke     3,160  1·2% 51 11·0%        57,095  2·0% 813 7·7% 
  Previous heart failure     6,825  2·6% 111 23·9%      138,045  4·8% 2148 20·4% 
  Any cardio-renal morbidity   31,790  12·0% 289 62·3%      624,995  21·7% 5833 55·4% 
The numbers of people in each category has been rounded to the nearest five to meet information governance rules. 
* - indicates a small number suppressed to meet information governance rules 






Figure 1a: Weekly number of deaths registered from January to May in people with Type 1 diabetes in England, 
2017-2020 
 






Figure 2: Forest plots showing adjusted hazard ratios for COVID-19 related death in people with Type 1 
(n=264,390) and Type 2 diabetes (n=2,874,020) in England up until 11th May 2020· 
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